Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer

Milevskiy, Michael J.G., Al-Ejeh, Fares, Saunus, Jodi M., Northwood, Korinne S., Bailey, Peter J., Betts, Joshua A., McCart Reed, Amy E., Nephew, Kenneth P., Stone, Andrew, Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015, Dowhan, Dennis H., Dray, Eloise, Shewan, Annette M., French, Juliet D., Edwards, Stacey L., Clark, Susan J., Lakhani, Sunil R. and Brown, Melissa A. 2016. Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer. Human Molecular Genetics 25 (15) , pp. 3269-3283. 10.1093/hmg/ddw177

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview

Abstract

Predicting response to endocrine therapy and survival in oestrogen receptor positive breast cancer is a significant clinical challenge and novel prognostic biomarkers are needed. Long-range regulators of gene expression are emerging as promising biomarkers and therapeutic targets for human diseases, so we have explored the potential of distal enhancer elements of non-coding RNAs in the prognostication of breast cancer survival. HOTAIR is a long non-coding RNA that is overexpressed, promotes metastasis and is predictive of decreased survival. Here, we describe a long-range transcriptional enhancer of the HOTAIR gene that binds several hormone receptors and associated transcription factors, interacts with the HOTAIR promoter and augments transcription. This enhancer is dependent on Forkhead-Box transcription factors and functionally interacts with a novel alternate HOTAIR promoter. HOTAIR expression is negatively regulated by oestrogen, positively regulated by FOXA1 and FOXM1, and is inversely correlated with oestrogen receptor and directly correlated with FOXM1 in breast tumours. The combination of HOTAIR and FOXM1 enables greater discrimination of endocrine therapy responders and non-responders in patients with oestrogen receptor positive breast cancer. Consistent with this, HOTAIR expression is increased in cell-line models of endocrine resistance. Analysis of breast cancer gene expression data indicates that HOTAIR is co-expressed with FOXA1 and FOXM1 in HER2-enriched tumours, and these factors enhance the prognostic power of HOTAIR in aggressive HER2+ breast tumours. Our study elucidates the transcriptional regulation of HOTAIR, identifies HOTAIR and its regulators as novel biomarkers of patient response to endocrine therapy and corroborates the importance of transcriptional enhancers in cancer.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Publisher:	Oxford University Press
ISSN:	0964-6906
Date of First Compliant Deposit:	26 July 2016
Date of Acceptance:	7 June 2016
Last Modified:	05 May 2023 17:11
URI:	https://orca.cardiff.ac.uk/id/eprint/93326

Citation Data

Cited 50 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item